Breast Cancer Clinical Trial

A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors

Summary

To investigate the safety and efficacy of nivolumab as a single agent or in combination with ipilimumab in 6 tumor types - triple-negative breast cancer (TNBC), gastric cancer (GC), pancreatic adenocarcinoma (PC), small cell lung cancer (SCLC), bladder cancer (BC), and ovarian cancer (OC). A combination of nivolumab with ipilimumab and cobimetinib is also investigated in PC.

View Full Description

Full Description

All tumor types are now closed for enrollment:

Triple Negative Breast Cancer

Gastric Cancer

Pancreatic Cancer

Small Cell Lung Cancer

Bladder Cancer

Ovarian Cancer

View Eligibility Criteria

Eligibility Criteria

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com

Inclusion Criteria:

Subjects with histologically or cytologically confirmed locally advanced or metastatic disease of the following tumor types:
Triple Negative Breast Cancer
Gastric Cancer
Pancreatic Cancer
Small Cell Lung Cancer
Bladder Cancer
Ovarian Cancer
Subjects must have measurable disease
Eastern Cooperative Oncology Group (ECOG) of 0 or 1
Adequate hematological and organ function as confirmed by laboratory values

Exclusion Criteria:

Active brain metastases or leptomeningeal metastases
Subjects with active, known or suspected autoimmune disease
Subjects with a condition requiring systemic treatment with either corticosteroids (>10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of treatment
Prior therapy with experimental anti-tumor vaccines; any T cell co-stimulation or checkpoint pathways, such as anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-CTLA-4 antibody, including Ipilimumab; or other medicines specifically targeting T cell is also prohibited

Study is for people with:

Breast Cancer

Phase:

Phase 1

Estimated Enrollment:

1163

Study ID:

NCT01928394

Recruitment Status:

Active, not recruiting

Sponsor:

Bristol-Myers Squibb

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 37 Locations for this study

See Locations Near You

Northwest Alabama Cancer Center, Pc
Muscle Shoals Alabama, 35661, United States
University Of Colorado
Aurora Colorado, 80045, United States
Local Institution - 0015
New Haven Connecticut, 06520, United States
Local Institution - 0046
Gainesville Florida, 32610, United States
Local Institution - 0021
Tampa Florida, 33612, United States
Local Institution - 0001
Atlanta Georgia, 30322, United States
Local Institution - 0004
Baltimore Maryland, 21287, United States
Dana Farber/Partners Cancercare, Inc.
Boston Massachusetts, 02215, United States
Local Institution - 0005
Boston Massachusetts, 02215, United States
Nebraska Cancer Specialists
Omaha Nebraska, 68130, United States
Local Institution - 0045
Mineola New York, 11501, United States
Local Institution - 0006
New York New York, 10065, United States
Local Institution - 0003
Charlotte North Carolina, 28204, United States
Local Institution - 0008
Durham North Carolina, 27710, United States
Local Institution - 0007
Portland Oregon, 97239, United States
Local Institution - 0011
Franklin Tennessee, 37067, United States
Local Institution - 0002
Nashville Tennessee, 37232, United States
Local Institution - 0009
Houston Texas, 77030, United States
Local Institution - 0042
Seattle Washington, 98104, United States
Local Institution - 0038
Toronto Ontario, M5G 2, Canada
Local Institution
Copenhagen , 2100, Denmark
Local Institution - 0014
Helsinki , 00029, Finland
Local Institution
Tampere , 33521, Finland
Local Institution
Bonn , 53105, Germany
Local Institution - 0026
Frankfurt , 60488, Germany
Local Institution - 0016
Heidelberg , 69120, Germany
Local Institution
Kassel , 34125, Germany
Local Institution - 0024
Bologna , 40138, Italy
Local Institution - 0019
Milano , 20133, Italy
Local Institution
Napoli , 80131, Italy
Local Institution - 0032
Padova , 35128, Italy
Local Institution
Barcelona , 08036, Spain
Local Institution
Madrid , 28040, Spain
Local Institution - 0017
Madrid , 28041, Spain
Local Institution - 0010
Madrid , 28050, Spain
Local Institution
London Greater London, SW3 6, United Kingdom
Local Institution - 0012
Glasgow Lanarkshire, G12 0, United Kingdom
Local Institution
Sutton Surrey, SM2 5, United Kingdom

How clear is this clinincal trial information?

Study is for people with:

Breast Cancer

Phase:

Phase 1

Estimated Enrollment:

1163

Study ID:

NCT01928394

Recruitment Status:

Active, not recruiting

Sponsor:


Bristol-Myers Squibb

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.